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Aim: Recent studies showed that increased chromosomal damage induced by ionizing radiation is observed among patients with 
different tumor types. The aim of the study was evaluation of chromosomal radiosensitivity in breast cancer (BC) patients (n = 37) 
and healthy women (n = 44). Methods: Chromosomal radiosensitivity was assessed with G0 and G2 assay. For G0 assay lymphocytes 
were exposed in vitro to 1,5 Gy of X-rays before culture setting. For G2 assay lymphocytes were irradiated with 0,5 Gy of X-rays 
after 47 h of incubation. Results: Significant differences in mean scores both of G0 and G2 assay between breast cancer patients 
and controls were observed indicating the increased chromosomal radiosensitivity of lymphocytes of cancer patients. 11% of healthy 
women and 38% of BC patients were determined to be radiosensitive with G2 assay. Conclusion: Obtained results support the 
concept of association between elevated individual G2 chromosomal radiosensitivity and predisposition to BC.
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C�rrent investigations of breast cancer �BC� develop-
ment revealed new genes and their variations infl�encing 
s�sceptibility and the cancer risk involved in cell f�nc-
tional transd�ction pathways. At the same time it was 
shown that they are responsible for individ�al reaction 
of cell to genotoxic agents s�ch as ionizing radiation and 
chemical m�tagens� development of sensitive/resistant 
cell phenotype. First evidence in favor of relationships 
between chromosome damage ind�ced by ionizing ra-
diation and high cancer predisposition was obtained from 
examinations of patients with rare heritable chromosome 
breakage syndromes [�� �]. Many of these disorders are 
ca�sed by specific m�tations in genes controlling DNA 
damage recognition� repair and elimination.  
Recent st�dies showed that chromosome damage 
ind�ced by ionizing radiation is also higher in peripheral 
blood lymphocytes �PBL� of cancer patients with diffe rent 
t�mor types. Increased chromosomal radiosensitivity 
was observed in ��% of �nselected breast� approxi-
mately ��% of colorectal� cervix and l�ng� head and neck 
cancer patients [��5]. BC patients with family history 
or with known genetic predisposition� s�ch as BRCA1/
BRCA2 m�tations� demonstrate essentially higher chro-
mosome damage than healthy individ�als [6�8]. M�ta-
tions in highly penetrant BRCA1 and BRCA2 genes are 
shown to acco�nt for �5% of familial and approximately 
for 5% of sporadic BC cases. At the same time ��% 
of gro�p of �nselected BC patients have demonstrated 
increased chromosomal damage in G� radiosensitivity 
assay. It was s�ggested that BC predisposition and high 
chromosomal radiosensitivity may be ca�sed by other 
BC s�sceptibility genes of low penetrance involved 
in DNA repair [9���]. Th�s polymorphic variants of can-
didate genes of moderate and low s�sceptibility risk� 
their effects in combination with environmental factors 
on BC etiology are in foc�s of recent investigations. 
It is shown that polymorphic alterations in ATM� BRIP1� 
BARD1� PALb2 NBS1, CYP17, NAT2, CYP1A1, FGFR2, 
GSTM1, GSTP1� ХRCC1, XRCC3, XRCC6, hRAD51 co�ld 
be essential risk factors for inherited and sporadic 
BC development and clinical o�tcome [����5]. Many 
of these genes are associated with DNA damage repair 
systems� the defects of which contrib�te to increased 
levels of chromosomal aberrations. From this point 
of view high inter-individ�al variations of chromosomal 
radiosensitivity of PBL of cancer patients and healthy 
individ�als reflect altered DNA repair efficiency� gene 
expression and cytogenetic parameters of radiosensiti-
vity can serve as possible cancer risk marker. 
In vitro radiation-ind�ced chromosome aberrations 
in PBL have been investigated as a basis for predic-
tive chromosomal assay for radiosensitivity eval�ation 
since the development of G�-chromatid break assay 
by Sanford et al. and its modification by Scott et al. 
[�6� �7]. Important direction of its application is de-
termination of patients’ risk to develop ac�te or late 
normal tiss�e responses after radiotherapy [�8]. In o�r 
previo�s investigations G�-assay was �sed to estimate 
chromosomal radiosensitivity in gro�p of healthy indi-
vid�als �n = ���� with the p�rpose of primary prevention 
of radiation-associated cancer [�9]. It was also shown 
that G� chromosomal radiosensitivity was �nrelated 
to sex and age of examined healthy donors. Another 
cytogenetic test — micron�cle�s �MN� G� radiosen-
sitivity assay was shown to be also relevant in as-
sessment of in vitro radiosensitivity and estimations 
of inter-indidvid�al variations of cytogenetic radio-
sensitivity parameters [�7� ��]. This st�dy presents 
eval�ation of inter-individ�al variations of G� and 
G� chromosomal radiosensitivity of PBL obtained from 
BC patients and healthy individ�als and correlation 
of its val�es with several clinical data.
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MATERIALS AND METHODS
Patients and normal control. Blood samples 
were obtained from �� healthy women� aged between 
�8�55 years �mean — �� years� witho�t cancer fam-
ily history and primary �7 BC patients aged between 
���8� years �mean — 56 years� with no previo�s cancer 
history and no prior radio- or chemotherapy. The t�-
mors were categorized as T� or T�� lymph node stat�s 
as N� or N�� distant metastases as M� �UICC TNM 
classification�� grade form I�III. Additionally 8 women 
aged between 5��77 years �mean — 6� years� with 
BC rec�rrences �all t�mors — T�N�M� stage� were 
tested in chromosomal radiosensitivity assays. Parallel 
c�lt�res of lymphocytes containing ��5 ml of hepari-
nized blood� ��5 ml RPMI-�6�� medi�m �Sigma-Aldrich� 
were established for each donor: to eval�ate spontane-
o�s level of chromosome aberrations� G� and G� assay 
scores. All donors gave informed concent for participa-
tion in the st�dy. The experimental protocols were ap-
proved by the Bioethical Committee of the Instit�te 
of Experimental Pathology� Oncology and Radiobiology 
of NAS of Ukraine.
G0 and G2 radiosensitivity assays. G�-assay 
was cond�cted for �� healthy donors� �� BC primary 
patients �all of them were tested in G�-assay�. Briefly� 
samples were irradiated with ��5 Gy dose of X-rays 
���� kV� �� mА� HVT ��5 mm C� + � mm Al� and � h later 
lymphocytes were stim�lated with phytohemaggl�-
tinin �Gibco/Invitrogen Co�. After �6 h of inc�bation 
��� μl of Colcemid sol�tion ��� μg/ml� Sigma-Aldrich� 
was added to block cells in metaphases. At �8 h c�lt�res 
were harvested according to common protocol [��].
For G� assay cell c�lt�res were irradiated with 
��5 Gy of X-rays after �7 h of inc�bation. At �� min 
later ��� μl of Colcemid sol�tion ��� μg/ml� was added 
and cells were harvested following � h. Thereafter 
cells were treated as described in [��]. Some minor 
proced�re changes made it possible to analyze cells 
in the first post-radiation mitosis. At least ��� meta-
phase cells were scored for each sample. Chromo-
some- and chromatid type aberrations were recorded 
in G� assay; chromatid and isochromatid breaks were 
analyzed in G� assay. G� and G� scores were obtained 
by s�btracting the spontaneo�s aberration yield from 
obtained after G� and G� cell irradiation.
Statistical analysis. The variances in chromosomal 
radiosensitivity was expressed as coefficient of variation 
�CV� of obtained cytogenetic parameters� determined 
as follow: CV = (SD/M)x100� where SD is the standard 
deviation� M — mean of aberration yield.
The �npaired St�dent t-test was �sed to com-
pare G� and G� scores. The proportions of G� and 
G� radiosensitive individ�als were calc�lated �sing 
9�th percentile as described in [�8]. The χ�-test was 
applied to compare differences in proportion of sensi-
tive donors of different gro�ps. Pearson correlation was 
�sed to ana lyze G� and G� assays data. The Mann — 
Whitney �MW� U test was applied to compare G� scores 
in s�bgro�ps of BC patients with different clinical cha-
racteristics. A significance level of p < �.�5 was �sed 
thro�gho�t.
RESULTS AND DISCUSSION
Recent st�dies have reported a significant pro-
portion of sporadic BC patients with high chromo-
somal radiation sensitivity of PBL according to the 
res�lts of G� and G� chromosomal radiosensitivity 
assays compared to healthy individ�als. The main 
idea of these assays in contrast to spontaneo�s level 
estimation is the analysis of chromosomal damage 
after low dose radiation expos�re of lymphocytes and 
estimation of inter-individ�al variations of obtained 
parameters. In G�-assay test-irradiation is applied 
d�ring G�/M — the most radiosensitive cell cycle point. 
Chromatid breaks observed in this case are seemed 
to be the res�lt of radiation ind�ced DNA do�ble strand 
breaks and markers of DNA repair capacity [��� ��]. 
To test the hypothesis whether cytogenetic parameters 
of radiation sensitivity associated with BC risk and 
to estimate inter-individ�al variations in chromosomal 
radiosensitivity of PBL of healthy women and sporadic 
BC patients we �sed both G� and G� assays. 
Res�lts of cytogenetic examination of BC patients 
and healthy controls are shown in Fig. �. The mean 
val�e of spontaneo�s freq�ency of chromosomal ab-
errations in gro�p of BC patients ��.9 ± �.6�� was not 
significantly higher than that of the healthy controls 
��.� ± �.��; �npaired t-test; p>�.�5�. There was low 
b�t significant difference in mean G� scores between 
BC patients and controls �t-test� p<�.�5�. Coefficients 
of variations �CV� of total yield of chromosome aber-
rations in G� assay were ��% for controls and ��% for 
BC patients. To indicate the proportion of normal and 
sensitive response to radiation� 9�th percentile of con-
trol val�es as c�t-off point for chromosomal radiosen-
sitivity was �sed as described in [�8]. Go chromosomal 
radiosensitivity was increased in ��% BC patients and 
in 7% individ�als in control gro�p with insignificant 
difference �χ� = �.66; p=�.��� �Table ��.
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Fig. 1. Spontaneo�s �SP�� G� and G� mean freq�encies �±SD� 
of chromosome aberrations observed in lymphocytes of healthy 
controls and BC patients
The mean overall G� score was essentially higher 
in BC gro�p than in controls — ���.�±��.� and 
6�.�±8.� respectively ��npaired t-test� p < �.����. 
CV of chromatid break yields ind�ced in G� phase 
in gro�p of healthy individ�als and BC patients were 
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higher than for G� scores — �� and �6%. ��.�% from 
healthy women �5/��� and �8% among BC patients 
���/�7� were determined as sensitive showing a sig-
nificant difference between proportions �χ� = �.��� p 
< �.����. Fig. � and � show the distrib�tions of G� and 
G� scores for healthy donors and BC patients. At the 
same time there was no correlation between G� and 
G� scores in both gro�ps: Pearson correlation coef-
ficient was �.�5 for controls and �.�� for cancer pa-
tients. There were no individ�als with sim�ltaneo�sly 
increased G� and G� scores in control gro�p and only 
� cancer patient had increased G� and G� chromo-
somal radiosensitivity val�es. 
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Fig. 2. Distrib�tion of radiation-ind�ced G� chromosome aber-
rations in gro�p of healthy women and BC patients
According to clinical data all of the examined BC pa-
tients had invasive adenocarcinoma� � cases were clas-
sified as mixed d�ctal lob�lar adenocarcinoma. Analysis 
has not revealed any significant correlations between 
G� scores and several specific clinical characteristics 
s�ch as t�mor size �T-category� MW test� p = �.���� 
lymph node involvement �N-category� MW test� p = 
�.�5�� t�mor grade �G� MW test� p = �.�8� and meno-
pa�sal stat�s �Table �� MW test� p = �.�6�. D�e to small 
n�mber of patients we can only notify the tendency 
of increased G� score association with t�mor grade 
III and pre-menopa�sal cancer development. There 
is contradictory literat�re data on the infl�ence of hor-
monal stat�s on chromosomal radiosensitivity of BC pa-
tients. Riches et al. [��] demonstrated that oestrogen 
receptor positive s�bpop�lation of BC patients had 
demonstrated increased G� radiosensitivity . It was also 
shown that high G� scores identifies a s�b-pop�lation 
of patients with distinctive t�mor characteristics and 
with a predicted improved prognosis as compared with 
those in the low radiosensitivity gro�p.
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Fig. 3. Distrib�tion of radiation-ind�ced G� chromatid breaks 
in gro�p of healthy women and BC patients
Table 1. Comparison of G0 and G2 scores in healthy controls and BC pa-
tients
As-
say
Healthy individuals BC patients
P2n M±SD CV, %
% 
of sen-
sitive 
individ-
uals (n)
n M±SD CV, %
% 
of sen-
sitive 
individ-
uals (n)
G0 30 32.8±3.0 10 7 (2) 30 46.6±4.5 12 20 (6)1 <0.05
G2 44 61.2±8.0 22 11 (5) 37 100.3±12.3 26 38 (14)1 <0.001
Notes: 1 — significant difference in proportions (p < 0.05, χ2-test); 2 — sig-
nificant difference from control (unpaired t-test)
Table 2. Association between clinical data and G2-scores of BC patients
Clinical characteristics n G2-scores1, М±SD % (n) of sensitive donors P2
T-category T1 27 97.8±10.2 37.0 (10) 0.42
T2 10 107±14.8 40 (4)
N-category N0 25 99.3±13.5 36 (9) 0.24
N1 13 102±14.3 38.5 (5)
Grade3 I 4 103.6±16.1 2
II 28 98.8±13.7 8
III 5 108.4±11.6 2
Menopause 
status
Pre 12 104.1±9.6 50 (6) 0.08
Post 25 98.48±12.6 32 (8)
All patients 37 100.3±12.3 37.8 (14)
Recurrence cases3 8 119.3±15.4 62.5 (5)
Notes: 1 — mean aberration frequency/100 metaphases; MW U test was ap-
plied to compare G2 scores in subgroups of BC patients with different clin-
ical characteristics; 2 — χ2-test for differences in the proportion of sensitive 
donors; 3 — unappropriate cohort for statistical analysis
To indicate correlation between G� chromosomal 
radiosensitivity and age of BC patients� they were 
separated into � s�bgro�ps — with high �n = ��� and 
normal �n = ��� G�-chromosomal radiosensitivity. 
Mean age of BC patients with high G� chromosomal 
radiosensitivity was �7 ± 7.� years and that in healthy 
controls — 66 ± �� years �p = �.���. Correlation be-
��� Experimental Oncology ��� �������� ���� ���ne�
tween high G� chromosomal radiosensitivity and early 
age of cancer onset co�ld be ca�sed by possible p�ta-
tive predisposition of yo�ng patients. Large proportion 
of patients with increased G� scores was observed 
among rec�rrence BC cases �⅝�. Obvio�sly� these 
preliminary data need more acc�rate examinations 
in selected representative cohorts of cancer patients.
The res�lts obtained in o�r st�dy confirm investi-
gations showing high G� chromosomal radiosensitiv-
ity among BC patients with no family cancer history 
compared to healthy women. Cytogenetic parameters 
obtained in G� assay are more appropriate to estimate 
chromosomal radiosensitivity compared to G� assay 
in BC gro�p� s�pporting concept of association between 
elevated G� chromosomal radiosensitivity and genetic 
predisposition to BC� impact of G�/M checkpoint 
on genomic stability and cancer risk [�5]. As it was s�g-
gested that abrogation of G�/M checkpoint increases 
chromosomal breakage [�6]� level of chromatid breaks 
observed after G� irradiation depends on DSB n�mber 
and efficiency of their repair� th�s inter-individ�al varia-
tions in G� scores can be ca�sed by differences in DNA 
repair capacity related to different mechanisms. Th�s 
data also testify for different DNA repair mechanisms 
�homological recombination or non-homological end 
joining� responsible for chromosome damage d�ring 
different cell cycle phases that co�ld be associated with 
BC development. Lack of correlation between G� and 
G� scores is reported by other research gro�ps who also 
spec�lated to different mechanisms of chromosomal 
radiosensitivity involving not only DNA repair efficiency 
b�t other cell cycle control checkpoints or chromatin 
conformations [�7]. Taking into consideration these 
findings special attention sho�ld be paid to individ�als 
from healthy controls with increased G� chromosomal 
radiosensitivity ���% in o�r st�dy�� to determine if they 
are in increased BC or radiation-associated cancer risk.
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